Analyst Jonna Kim of TD Cowen maintained a Hold rating on Hims & Hers Health, boosting the price target to $48.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jonna Kim has given his Hold rating due to a combination of factors impacting Hims & Hers Health’s performance. The company’s recent quarter showed mixed results with EBITDA surpassing expectations, but sales falling short. The guidance for the third quarter of 2025 suggests sales might align with expectations, but EBITDA is anticipated to be lower as the company continues to invest in growth initiatives.
Hims & Hers Health is focusing on building infrastructure for future growth, including new specialties, lab testing, and international expansion. However, these investments are expected to pressure margins in the near term. Additionally, challenges such as transitioning subscribers to daily offerings in the sexual health segment and declining GLP-1 revenue are present. These factors, along with potential regulatory risks, contribute to the Hold rating, despite a raised price target to $48.
According to TipRanks, Kim is a 4-star analyst with an average return of 16.7% and a 37.14% success rate. Kim covers the Consumer Cyclical sector, focusing on stocks such as Gap Inc, American Eagle, and Victoria’s Secret.